DE19807426A1 - Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs - Google Patents
Verfahren zur Behandlung von Erkrankungen oder Störungen des InnenohrsInfo
- Publication number
- DE19807426A1 DE19807426A1 DE19807426A DE19807426A DE19807426A1 DE 19807426 A1 DE19807426 A1 DE 19807426A1 DE 19807426 A DE19807426 A DE 19807426A DE 19807426 A DE19807426 A DE 19807426A DE 19807426 A1 DE19807426 A1 DE 19807426A1
- Authority
- DE
- Germany
- Prior art keywords
- active ingredient
- inner ear
- use according
- cells
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000003027 ear inner Anatomy 0.000 title claims abstract description 53
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 20
- 201000010099 disease Diseases 0.000 title claims abstract description 11
- 208000035475 disorder Diseases 0.000 title abstract description 8
- 238000000034 method Methods 0.000 title abstract description 8
- 230000001953 sensory effect Effects 0.000 claims abstract description 55
- 239000004480 active ingredient Substances 0.000 claims abstract description 43
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims abstract description 23
- 230000006378 damage Effects 0.000 claims abstract description 20
- 210000004209 hair Anatomy 0.000 claims abstract description 13
- 230000035755 proliferation Effects 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 108
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 25
- 102000039446 nucleic acids Human genes 0.000 claims description 25
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 230000008929 regeneration Effects 0.000 claims description 15
- 238000011069 regeneration method Methods 0.000 claims description 15
- 102000016736 Cyclin Human genes 0.000 claims description 13
- 108050006400 Cyclin Proteins 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 229940043355 kinase inhibitor Drugs 0.000 claims description 12
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 12
- 210000002768 hair cell Anatomy 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 9
- 239000013603 viral vector Substances 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 102000053602 DNA Human genes 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 3
- 241000702421 Dependoparvovirus Species 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 241000701161 unidentified adenovirus Species 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 208000027601 Inner ear disease Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000002479 lipoplex Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 abstract 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 abstract 1
- 230000001172 regenerating effect Effects 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 description 12
- 210000003477 cochlea Anatomy 0.000 description 12
- 210000000981 epithelium Anatomy 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 9
- 230000003993 interaction Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 230000032823 cell division Effects 0.000 description 7
- 239000003184 complementary RNA Substances 0.000 description 7
- 108020005544 Antisense RNA Proteins 0.000 description 6
- 238000011813 knockout mouse model Methods 0.000 description 6
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 5
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 5
- 206010011878 Deafness Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 210000002985 organ of corti Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000016354 hearing loss disease Diseases 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 210000000243 deiters cell Anatomy 0.000 description 3
- 210000000067 inner hair cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000635 electron micrograph Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000004049 perilymph Anatomy 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010048865 Hypoacusis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- -1 Lipid compounds Chemical class 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000721 basilar membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000959 ear middle Anatomy 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 210000000645 stria vascularis Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19807426A DE19807426A1 (de) | 1998-02-23 | 1998-02-23 | Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs |
| CA002320717A CA2320717C (en) | 1998-02-23 | 1999-02-23 | Method for the treatment of diseases or disorders of the inner ear |
| DK99910259T DK1056467T3 (da) | 1998-02-23 | 1999-02-23 | Metode til behandling af sygdomme eller lidelser i det indre øre |
| AU29281/99A AU763868B2 (en) | 1998-02-23 | 1999-02-23 | Method for the treatment of diseases or disorders of the inner ear |
| PT99910259T PT1056467E (pt) | 1998-02-23 | 1999-02-23 | Processo para o tratamento de doencas ou perturbacoes do ouvido interno |
| US09/622,719 US7087581B1 (en) | 1998-02-23 | 1999-02-23 | Method for the treatment of diseases or disorders of the inner ear |
| ES99910259T ES2211055T3 (es) | 1998-02-23 | 1999-02-23 | Procedimiento para el tratamiento de enfermedades o trastornos del oido interno. |
| JP2000532105A JP2002503687A (ja) | 1998-02-23 | 1999-02-23 | 内耳の疾患又は機能障害の治療方法 |
| EP99910259A EP1056467B1 (de) | 1998-02-23 | 1999-02-23 | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs |
| AT99910259T ATE250936T1 (de) | 1998-02-23 | 1999-02-23 | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs |
| PCT/EP1999/001153 WO1999042088A2 (de) | 1998-02-23 | 1999-02-23 | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs |
| DE59907195T DE59907195D1 (de) | 1998-02-23 | 1999-02-23 | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs |
| US10/458,108 US7132406B2 (en) | 1998-02-23 | 2003-06-09 | Stimulation of cellular regeneration and differentiation in the inner ear |
| US11/588,910 US7741303B2 (en) | 1998-02-23 | 2006-10-27 | Stimulation of cellular regeneration and differentiation in the inner ear |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19807426A DE19807426A1 (de) | 1998-02-23 | 1998-02-23 | Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19807426A1 true DE19807426A1 (de) | 1999-10-14 |
Family
ID=7858563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19807426A Withdrawn DE19807426A1 (de) | 1998-02-23 | 1998-02-23 | Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs |
| DE59907195T Expired - Fee Related DE59907195D1 (de) | 1998-02-23 | 1999-02-23 | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE59907195T Expired - Fee Related DE59907195D1 (de) | 1998-02-23 | 1999-02-23 | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7087581B1 (enExample) |
| EP (1) | EP1056467B1 (enExample) |
| JP (1) | JP2002503687A (enExample) |
| AT (1) | ATE250936T1 (enExample) |
| AU (1) | AU763868B2 (enExample) |
| CA (1) | CA2320717C (enExample) |
| DE (2) | DE19807426A1 (enExample) |
| DK (1) | DK1056467T3 (enExample) |
| ES (1) | ES2211055T3 (enExample) |
| PT (1) | PT1056467E (enExample) |
| WO (1) | WO1999042088A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2325198A1 (en) | 1999-06-01 | 2011-05-25 | Baylor College Of Medicine | Compositions and methods for the therapeutic use of an atonal-associated sequence |
| DE10027777A1 (de) * | 2000-06-07 | 2001-12-13 | Otogene Ag | Transfektionsverfahren |
| CA2412764C (en) * | 2000-07-11 | 2014-06-03 | Sound Pharmaceuticals Incorporated | Stimulation of cellular regeneration and differentiation in the inner ear |
| JP4533144B2 (ja) | 2002-10-02 | 2010-09-01 | アンジェスＭｇ株式会社 | 聴覚機能障害用医薬 |
| EP1585523B1 (en) * | 2002-12-17 | 2008-10-01 | Centre National De La Recherche Scientifique (Cnrs) | Use of purine derivatives for inducing differentiation of supernumerary hair cells and deiters' cells in the developing organ of corti for treating deafness |
| EP2293800B1 (en) | 2008-06-06 | 2016-10-05 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
| DE102010007281A1 (de) * | 2010-02-08 | 2011-08-11 | EMC microcollections GmbH, 72070 | Neue Aminoalkyl-oxazol- und Aminoalkyl-thiazolcarbonsäureamide und ihre Anwendung zur Stimulation der endogenen situ Regeneration von Haarsinneszellen im Corti'schen Organ des Innenohres beim Säuger |
| RU2480195C1 (ru) * | 2011-11-02 | 2013-04-27 | Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава РФ") | Способ лечения заболеваний внутреннего уха |
| EP2802657B1 (en) | 2012-01-12 | 2018-05-02 | Quark Pharmaceuticals, Inc. | Combination therapy for treating hearing and balance disorders |
| WO2013134022A1 (en) * | 2012-03-05 | 2013-09-12 | Wake Forest University Health Sciences | Regeneration of inner ear cells |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004762A1 (de) * | 1995-08-02 | 1997-02-13 | Hans Peter Zenner | Verwendung von adamantan-derivaten zur behandlung von erkrankungen des innenohrs |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0866716A4 (en) | 1995-11-13 | 2002-05-02 | Cambridge Neuroscience Inc | METHOD FOR TREATING DISORDERS OF THE NON-VISUAL SENSORIC EPITHEL |
| US5962224A (en) * | 1995-12-19 | 1999-10-05 | Dana-Farber Cancer Institute | Isolated DNA encoding p62 polypeptides and uses therefor |
| AU3591597A (en) | 1996-06-28 | 1998-01-21 | Regents Of The University Of California, The | Transformation and genetherapy of cells of the inner ear |
| AU4600297A (en) | 1996-09-27 | 1998-04-17 | Trustees Of The University Of Pennsylvania, The | Novel methods for inducing proliferation in auditory receptor epithelium |
| US6043221A (en) * | 1997-07-30 | 2000-03-28 | Amgen Inc. | Method for preventing and treating hearing loss using a neuturin protein product |
-
1998
- 1998-02-23 DE DE19807426A patent/DE19807426A1/de not_active Withdrawn
-
1999
- 1999-02-23 DE DE59907195T patent/DE59907195D1/de not_active Expired - Fee Related
- 1999-02-23 PT PT99910259T patent/PT1056467E/pt unknown
- 1999-02-23 WO PCT/EP1999/001153 patent/WO1999042088A2/de not_active Ceased
- 1999-02-23 DK DK99910259T patent/DK1056467T3/da active
- 1999-02-23 CA CA002320717A patent/CA2320717C/en not_active Expired - Fee Related
- 1999-02-23 ES ES99910259T patent/ES2211055T3/es not_active Expired - Lifetime
- 1999-02-23 EP EP99910259A patent/EP1056467B1/de not_active Expired - Lifetime
- 1999-02-23 US US09/622,719 patent/US7087581B1/en not_active Expired - Lifetime
- 1999-02-23 AU AU29281/99A patent/AU763868B2/en not_active Ceased
- 1999-02-23 AT AT99910259T patent/ATE250936T1/de not_active IP Right Cessation
- 1999-02-23 JP JP2000532105A patent/JP2002503687A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997004762A1 (de) * | 1995-08-02 | 1997-02-13 | Hans Peter Zenner | Verwendung von adamantan-derivaten zur behandlung von erkrankungen des innenohrs |
Non-Patent Citations (8)
| Title |
|---|
| ACS Abstracts: Ref. 85:13565 * |
| ADLER,Henry J., RAPHAEL,Yehoash: New hair cells arise from supporting cell conversion in the acoustically damaged chick inner ear. In: Neuroscience Letters 205, 1996, S.17-20 * |
| BIOSIS Abstracts: Ref. 1997:441346 * |
| EMBASE Abstract, Ref. 97130705 * |
| LEON,Y., et.al.: Developmental Regulation of Fos- Protein during Proliferative Growth of the Otic Vesicle and Its Relation to Differentation Induced by Retinoic Acid. In: Developmental, Biology 167, 1995, S.75-86 * |
| Ref. 129:62545 * |
| Ref. 1997:408589 * |
| SPENCER-DENE,Bradley, et.al.: Distribution of, and a putative role for, the cell-surface neutral metalloendopeptidases during mammalian craniofacial development. In: Development 120, 1994, S.3213-3226 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999042088A3 (de) | 2000-03-02 |
| EP1056467A2 (de) | 2000-12-06 |
| CA2320717C (en) | 2009-03-24 |
| WO1999042088A2 (de) | 1999-08-26 |
| DE59907195D1 (de) | 2003-11-06 |
| ES2211055T3 (es) | 2004-07-01 |
| AU2928199A (en) | 1999-09-06 |
| ATE250936T1 (de) | 2003-10-15 |
| PT1056467E (pt) | 2004-02-27 |
| CA2320717A1 (en) | 1999-08-26 |
| US7087581B1 (en) | 2006-08-08 |
| AU763868B2 (en) | 2003-07-31 |
| JP2002503687A (ja) | 2002-02-05 |
| EP1056467B1 (de) | 2003-10-01 |
| DK1056467T3 (da) | 2004-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60302348T2 (de) | Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen | |
| DE69911400T2 (de) | Zusammensetzungen enhaltende 5-hydroxyindol als Modulator eines nikotinischen Rezeptors | |
| DE69122956T2 (de) | Verfahren und zusammensetzungen zur hemmung der angiogenese | |
| DE19917990A1 (de) | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk | |
| EP1056467B1 (de) | Verfahren zur behandlung von erkrankungen oder störungen des innenohrs | |
| DE19748763A1 (de) | Verwendung von Vasopressin-Antagonisten | |
| DE102008014880A1 (de) | Antientzündliches Polypeptid | |
| DE10239531A1 (de) | Prophylaxe und Therapie von Infektionserkrankungen | |
| EP2991664B1 (de) | Agenzien zur prävention und therapie von folgeerkrankungen von hiv und anderer viraler infektionen | |
| EP3747454A1 (de) | Amyloid-beta-bindende peptide und deren verwendung für die therapie und die diagnose der alzheimerschen demenz | |
| Bulloch et al. | Neuronal plasticity in the adult invertebrate nervous system | |
| DE69932834T2 (de) | Neue Peptide | |
| WO2011137886A1 (de) | Mittel zur behandlung der alzheimerschen demenz | |
| EP1054682A2 (de) | Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen | |
| WO1999061045A1 (de) | Topisch anwendbares arzneimittel zur behandlung von virusinfektionen | |
| KR20010077131A (ko) | 인삼 추출물을 포함하는 기억력 증진제 | |
| DE19915465A1 (de) | Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten | |
| DE102021107546A1 (de) | Verwendung von d-enantiomeren peptidliganden von monomerem tau für die therapie verschiedener tauopathien | |
| DE19625582A1 (de) | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen | |
| DE60031132T2 (de) | Zusammensetzungen zur eröffnung der wasserkanäle und medizinische zusammensetzungen zur opthalmischer verwendung | |
| DE10035854A1 (de) | Schlangentoxin und dessen Verwendung als Arzneimittel | |
| DE60107942T2 (de) | Verwendung von chrysanthon-naturstoffen, die eine antiangiogene wirkung haben | |
| Kraus | Identification of small molecule inhibitors of clinically relevant human polyomavirus infections | |
| DE102006011747A1 (de) | Dermatologische und/oder kosmetische Zubereitungen | |
| Holsboer | Zukunftsstrategien für die Entdeckung neuer Antidepressiva |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OM8 | Search report available as to paragraph 43 lit. 1 sentence 1 patent law | ||
| 8127 | New person/name/address of the applicant |
Owner name: OTOGENE AG, 72076 TUEBINGEN, DE |
|
| 8139 | Disposal/non-payment of the annual fee |